Strides partners with Ascent Capital to unlock value in Pivot Path

Strides Pharma Science has announced a strategic investment in its wholly owned subsidiary, Pivot Path, by a consortium led by Ascent Capital, along with co-investor Vintage Classic. The transaction values Pivot Path at approximately ₹2.3 billion on a post-money basis and is aimed at accelerating the company’s next phase of growth.

Under the transaction, Strides will realise around ₹1 billion while retaining an approximately 20 per cent ownership stake in Pivot Path. The deal also includes a primary capital infusion of ₹500 million to support the company’s expansion strategy and technology investments.

According to Strides, the transaction aligns with its strategy of creating, scaling and unlocking value from high-potential businesses while continuing to participate in their future growth. The proceeds will also strengthen the company’s balance sheet while providing growth capital for Pivot Path.

Pivot Path originated within Arco Lab, Strides’ Global Capability Centre (GCC), where it developed expertise across life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services. As demand from external pharmaceutical and life sciences companies increased, the business evolved into an independent platform serving leading industry customers.

To support its next phase of growth, strengthen its ability to serve global customers, build agentic AI platforms and access external capital, the business was carved out into Pivot Path through a Scheme of Arrangement approved by the National Company Law Tribunal (NCLT) in May 2026. Following completion of the transaction, Pivot Path will be reclassified as an associate of Strides.

The transaction was undertaken based on an independent valuation conducted by a SEBI-registered merchant banker, reflecting Pivot Path’s differentiated capabilities, established customer relationships and long-term growth potential.

For FY26, the carved-out business reported revenue of ₹1,447 million, including revenue from services rendered to Strides, and EBITDA of ₹169 million, highlighting its profitable operating platform and growth trajectory.

Commenting on the transaction, Badree Komandur, MD & Group CEO, Strides, said, “Pivot Path exemplifies Strides’ proven capability to identify, incubate and scale high-potential businesses. Over the past years, we have built a platform with specialised capabilities, a growing customer base and a strong foundation for future growth.As the business enters its next phase, we believe this is the right time to bring in a strategic investment partner with the expertise and capital to accelerate its growth. This transaction unlocks value for Strides, provides Pivot Path with the resources to scale independently, and allows Strides to retain meaningful participation in its future success. We are delighted to partner with Ascent Capital and its investor consortium, whose experience in building high-growth businesses will support Pivot Path’s long-term ambitions.”

Raja Kumar, MD & Founder, Ascent Capital, said, “Pivot Path brings deep domain expertise across the core, non-discretionary segments of the pharmaceutical industry, capabilities that have been rigorously honed within the Strides stable. As an Independent entity, Pivot Path is exceptionally well positioned to combine the power of technology and Agentic-AI with its 400+ subject matter experts in building purpose-built solutions that enable global customers to manage their compliance, digital transformation, and drug safety requirements with greater speed, precision, cost effectiveness and confidence. We are excited to partner with Pivot Path’s accomplished management team as the company enters its next phase of growth in one of the most dynamic environments the industry has seen.”

The post Strides partners with Ascent Capital to unlock value in Pivot Path appeared first on Express Pharma.